TWA
CBAY

TCI Wealth Advisors’s Cymabay Therapeutics CBAY Stock Holding History

TCI Wealth Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-341
Closed -$2.97K – 2425
2023
Q1 		$2.97K Buy
+341
New +$2.73K ﹤0.01% 1853
2018
Q3 		– Sell
-27
Closed – – 1620
2018
Q2 		$0 Buy
+27
New +$338 ﹤0.01% 1629

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

TCI Wealth Advisors's CBAY Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 341 shares — an estimated $2.97K sold.

TCI Wealth Advisors first reported a position in CBAY in Q2 2018 and held it in 2 quarters. The position peaked at $2.97K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 341 Cymabay Therapeutics shares in Q2 2023, an estimated $2.97K.
  • TCI Wealth Advisors first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 2 quarters.
  • TCI Wealth Advisors's Cymabay Therapeutics position peaked at $2.97K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.